Innovation Pharmaceuticals Inc (IPIX)

[PJ007]

This is a great post by Mo and worthy of a sticky:

My original interest in investing in IPIX was because of the tremendous potential of Kevetrin. It was good to see yesterday’s PR regarding Kevetrin in a leading oncology journal, Oncology Reports. The next key advancement for Kevetrin will be the completion and testing of an oral delivery system. I believe that will happen as soon as funding permits which could be very soon.

IMO the MM’s have been keeping IPIX SP in a very narrow range. I think the criminals have felt empowered to heavily manipulate IPIX SP up through Labor Day but they are well aware that they could get bombarded with positive news from IPIX between now and November. My guess is that Leo will have 10 or more PR’s in the next 8-10 weeks including:

- Draft copy of peer review from either/both RBL & PHRI
- Detailed description of upcoming B-CV19 human trial
- Initiation of B-CV19 human trial
- CRO announced to start B-IBD UC Q4 trial
- Initial Government Grant funding to cover CV-19 human trial
- Positive interim results from B-CV-19 human trial
- Competitive positioning on B-CV19 as gold standard treatment vs
Remdesivir and others.
- Successful conclusion to B-CV19 human trial
- Emergency Use Approval for B-CV19
- Larger Government Grant with revenue commitment to IPIX for
B-CV19
- Initiation of B-IBD UC phase 2 trial
- Alfasigma B-IBD UP/UPS trial advancement
- Announced completion and testing of Kevetrin oral delivery system
- B-OM Phase 3 initiation if funding allows
- Unexpected surprise like the previously announced European subsidiary
or the recent Fox Chase partnership agreement
- A European or International Distribution Partnership for B-CV19

If the above milestones (especially the items in bold above) are met and announced we should see some incredible panicking from the criminals and see some huge volume increases with new investor demand driving IPIX SP in an upwards trajectory. It should be an exciting next few weeks to be an IPIX investor.